ÖZET
Sonuç:
Serum endokan seviyeleri, başvurudaki klinik durumu tahmin etmek için yararlı bir biyobelirteçtir ve COVID-19 hastalarının prognozunu ve sonuçlarını öngörebilir.
Bulgular:
Kritik hastaların ortalama yaşı stabil hastalardan anlamlı derecede yüksekti (71,00±13,27 ve 53,36±17,80; p<0,001). Kritik hastalarda kan ve serum parametreleri (C-reaktif protein, ferritin, prokalsitonin, laktat, nötrofil-lenfosit oranı, D-dimer, troponin T, üre, kreatinin, beyaz kan hücresi ve uluslararası normalleştirilmiş oran) anlamlı olarak daha yüksekti (p<0,05). Kritik hastalarda serum endokan düzeyleri anlamlı olarak yüksekti (518,9±513.31 ng/mL; p<0,001). Endokan, yaş, laktat ve troponin T’nin kritik hastaları stabil hastalardan ayırt etmede önemli ölçüde etkili olduğu bulundu. Kritik hastalar için 244,9 ng/mL endocan seviyesinin %88,9 duyarlılığa ve %63,6 özgüllüğe sahip olduğu görüldü.
Yöntem:
Çalışmaya, polimeraz zincir reaksiyon testi pozitif olan, 18 yaşından büyük, 44’ü stabil, 36’sı kritik durumda, ilk başvuru şikayeti kalp krizi veya iskemik inme olmayan toplam 80 COVID-19 hastası dahil edildi. Hastaların özellikleri ve klinik sonuçları, hematolojik ve biyokimyasal parametreleri, endokan düzeyleri, toraks bilgisayarlı tomografileri, tedavi yaklaşımları, vital bulguları ve COVID-19 semptomları değerlendirildi.
Amaç:
Çalışmada primer amaç, Koronavirüs hastalığı-2019 (COVID-19) hastalarında serum endokan düzeyleri ile klinik durumları arasındaki ilişkiyi değerlendirmekti. Sekonder olarak ise klinik sonuçlar açısından serum endokan seviyeleri ile diğer enflamatuvar parametreler arasındaki ilişkileri ortaya koymayı hedefledik.
Anahtar Kelimeler:
COVID-19, endokan, prognoz
Kaynaklar
1
Roberts CM, Levi M, McKee M, Schilling R, Lim WS, Grocott MPW. COVID-19: a complex multisystem disorder. Br J Anaesth 2020;125(3):238-242.
2
Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. Mayo Clin Proc 2020;95(8):1621-1631.
3
Islam MA, Alam SS, Kundu S, Hossan T, Kamal MA, Cavestro C. Prevalence of Headache in Patients With Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of 14,275 Patients. Front Neurol 2020;11:562634.
4
Islam MA, Kundu S, Alam SS, Hossan T, Kamal MA, Hassan R. Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients. PLoS One 2021;16(4):e0249788.
5
Hentsch L, Cocetta S, Allali G, Santana I, Eason R, Adam E, et al. Breathlessness and COVID-19: A Call for Research. Respiration 2021;100(10):1016-1026.
6
Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. Int J Cardiol 2020;309:70-77.
7
Medetalibeyoglu A, Emet S, Kose M, Akpinar TS, Senkal N, Catma Y, et al. Serum Endocan Levels on Admission Are Associated With Worse Clinical Outcomes in COVID-19 Patients: A Pilot Study. Angiology 2021;72(2):187-193.
8
Miesbach W, Makris M. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Clin Appl Thromb Hemost 2020;26:1076029620938149.
9
Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020;58(7):1021-1028.
10
Zhu Z, Wang M, Lin W, Cai Q, Zhang L, Chen D, et al. Cardiac biomarkers, cardiac injury, and comorbidities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Immun Inflamm Dis 2021;9(4):1071-1100.
11
Ulloque-Badaracco JR, Ivan Salas-Tello W, Al-Kassab-Córdova A, Alarcón-Braga EA, Benites-Zapata VA, Maguiña JL, et al. Prognostic value of neutrophil-to-lymphocyte ratio in COVID-19 patients: A systematic review and meta-analysis. Int J Clin Pract 2021;75(11):e14596.
12
Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Celik T, Iyisoy A. Endocan: A novel inflammatory indicator in cardiovascular disease? Atherosclerosis 2015;243(1):339-343.
13
Yücel M, Kotan D, Gurol Çiftçi G, Çiftçi IH, Cikriklar HI. Serum levels of endocan, claudin-5 and cytokines in migraine. Eur Rev Med Pharmacol Sci 2016;20(5):930-936.
14
Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996;271(34):20458-20464.
15
Gerritsen ME, Tomlinson JE, Zlot C, Ziman M, Hwang S. Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol 2003;140(4):595-610.
16
Arman Y, Akpinar TS, Kose M, Emet S, Yuruyen G, Akarsu M, et al. Effect of Glycemic Regulation on Endocan Levels in Patients With Diabetes: A Preliminary Study. Angiology 2016;67(3):239-244.
17
Kose M, Emet S, Akpinar TS, Kocaaga M, Cakmak R, Akarsu M, et al. Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study. Angiology 2015;66(8):727-731.
18
Oktar SF, Guney I, Eren SA, Oktar L, Kosar K, Buyukterzi Z, et al. Serum endocan levels, carotid intima-media thickness and microalbuminuria in patients with newly diagnosed hypertension. Clin Exp Hypertens 2019;41(8):787-794.
19
Kuluöztürk M, İn E, İlhan N. Endocan as a marker of disease severity in pulmonary thromboembolism. Clin Respir J 2019;13:773-780.
20
Güzel A, Duran L, Köksal N, Torun AC, Alaçam H, Ekiz BC, et al. Evaluation of serum endothelial cell specific molecule-1 (endocan) levels as a biomarker in patients with pulmonary thromboembolism. Blood Coagul Fibrinolysis 2014;25(3):272-276.
21
Walborn A, Rondina M, Mosier M, Fareed J, Hoppensteadt D. Endothelial Dysfunction Is Associated with Mortality and Severity of Coagulopathy in Patients with Sepsis and Disseminated Intravascular Coagulation. Clin Appl Thromb Hemost 2019;25:1076029619852163.
22
Pascreau T, Tcherakian C, Zuber B, Farfour E, Vasse M, Lassalle P. A high blood endocan profile during COVID-19 distinguishes moderate from severe acute respiratory distress syndrome. Crit Care 2021;25(1):166.
23
Zhao T, Kecheng Y, Zhao X, Hu X, Zhu J, Wang Y, et al. The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: A meta-analysis. Medicine (Baltimore) 2018;97(49):e13407.
24
Yilmaz MI, Siriopol D, Saglam M, Kurt YG, Unal HU, Eyileten T, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int 2014;86(6):1213-1220.
25
Balta I, Balta S, Demirkol S, Mikhailidis DP, Celik T, Akhan M, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol 2013;169(5):1066-1070.
26
Balta I, Balta S, Koryurek OM, Demirkol S, Mikhailidis DP, Celik T, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol 2014;70(2):291-296.
27
Celık T, Balta S, Karaman M, Ahmet Ay S, Demırkol S, Ozturk C, et al. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press 2015;24(1):55-60.
28
Delehedde M, Devenyns L, Maurage CA, Vivès RR. Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan. Int J Cell Biol 2013;2013:705027.
29
Yang J, Yang Q, Yu S, Zhang X. Endocan: A new marker for cancer and a target for cancer therapy. Biomed Rep 2015;3(3):279-283.
30
Lv Y, Zhang Y, Shi W, Liu J, Li Y, Zhou Z, et al. The Association Between Endocan Levels and Subclinical Atherosclerosis in Patients With Type 2 Diabetes Mellitus. Am J Med Sci 2017;353(5):433-438.
31
Akil E, Alp R, Aluclu MU, Acar A, Kaplan I. Serum endocan levels in multiple sclerosis relapse and remission. Eur Rev Med Pharmacol Sci 2021;25(11):4091-4098.
32
Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 2020;383(2):120-128.
33
Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol 2020;5(7):831-840.
34
Görgün S, Cindoruk Ş, Özgen E, Yadigaroğlu M, Demir MT, Yücel M, et al. Diagnostic and Prognostic Value of Serum Endocan Levels in Patients With COVID-19. Angiology 2021;72(10):942-946.
35
Shi J, Li Y, Zhou X, Zhang Q, Ye X, Wu Z, et al. Lactate dehydrogenase and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested case-control study. BMC Med 2020;18(1):168.
36
Hu H, Du H, Li J, Wang Y, Wu X, Wang C, et al. Early prediction and identification for severe patients during the pandemic of COVID-19: A severe COVID-19 risk model constructed by multivariate logistic regression analysis. J Glob Health 2020;10(2):020510.
37
Bruno RR, Wernly B, Flaatten H, Fjølner J, Artigas A, Bollen Pinto B, et al. Lactate is associated with mortality in very old intensive care patients suffering from COVID-19: results from an international observational study of 2860 patients. Ann Intensive Care 2021;11(1):128.
38
Ide S, Hayama H, Asai Y, Terada M, Nomoto H, Kutsuna S, et al. Evaluation of High-Sensitivity Cardiac Troponin T Levels in Japanese Patients Recently Recovered From Coronavirus Disease 2019. Circ J 2021;85(6):944-947.
39
Schiavone M, Gasperetti A, Mancone M, Kaplan AV, Gobbi C, Mascioli G, et al. Redefining the Prognostic Value of High-Sensitivity Troponin in COVID-19 Patients: The Importance of Concomitant Coronary Artery Disease. J Clin Med 2020;9(10):3263.
40
Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med2020;180(8):1081-1089.
